glp 1 agonists review GLP-1 receptor and next-generation metabolic hormone therapies in chronic kidney disease Table 1 from Glucagon-Like Peptide-1

Further, warnings on GLP-1RAs have recently been strengthened over rare cases of necrotising and fatal pancreatitis following use

[DOI] [PMC free article] [PubMed] [Google Scholar] 111.van Bloemendaal L, Veltman DJ, ten Kulve JS, et al

EMA - European Medicines Agency

"By improving baseline risk factors, GLP-1 drugs may contribute to mortality improvements over time, saving millions from premature death," the researchers commented

Patients taking GLP-1s may lose weight, improve glucose control, reduce cardiometabolic risk, and engage more intensively with health care

Besides decreased body weight and glycemia, a decrease in systolic blood pressure by 2.22 mmHg was noted across 33 clinical trials [74], thus decreasing the incidence of hypertension, one of the main risk factors involved in the development of diabetic nephropathy [75]